Welcome to our dedicated page for REDWOOD AI news (Ticker: RDWCF), a resource for investors and traders seeking the latest updates and insights on REDWOOD AI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect REDWOOD AI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of REDWOOD AI's position in the market.
Redwood AI (CSE:AIRX, OTCQB:RDWCF) closed its previously announced private placement with a single U.S. fundamental institutional investor, issuing up to 1,663,000 special warrants at $2.11 each for gross proceeds of up to $3.5 million. Each special warrant will automatically convert, for no additional consideration, into one unit, consisting of one common share and one warrant.
Each warrant allows the purchase of one common share at $2.48 for 60 months after closing. Net proceeds are expected to fund working capital and general corporate purposes. If a prospectus supplement is not filed within 90 days of closing, each special warrant will become exercisable for 1.10 units instead of one. Maxim Group acted as exclusive placement agent, and the securities are subject to Canadian and U.S. resale restrictions.
Redwood AI (CSE:AIRX, OTCQB:RDWCF) has priced a private placement of 1,663,000 Special Warrants at $2.11 each, for expected gross proceeds of approximately $3.5 million with a single U.S. fundamental institutional investor. Maxim Group is the exclusive placement agent, and closing is expected on July 20, 2026, subject to Canadian Securities Exchange approval.
Each Special Warrant will automatically convert, for no additional consideration, into one Unit, consisting of one common share and one Warrant. Each Warrant allows purchase of one share at $2.48 for 60 months. If a prospectus supplement is not filed within 90 days after closing, each Special Warrant will instead be exercisable for 1.10 Units. Redwood AI plans to use net proceeds for working capital and general corporate purposes, and the securities will be subject to Canadian and U.S. resale restrictions.
Redwood AI (CSE:AIRX, OTCQB:RDWCF) has been added to the CSE25 Index after the Canadian Securities Exchange’s latest quarterly rebalancing.
The CSE25 includes the 25 largest CSE-listed companies by market cap and represents over 75% of the CSE Composite Index’s market capitalization, potentially increasing Redwood’s market visibility.
Redwood AI (OTCQB:RDWCF) signed a definitive share purchase agreement to acquire all shares of Quantum.IQ Technologies, expanding into quantum‑resistant cybersecurity, cryptographic intelligence and enterprise security infrastructure.
Payment totals 14,033,558 Redwood shares, split between 7,033,558 time‑released escrow shares and up to 7,000,000 milestone‑based shares, subject to revenue, EBITDA and pilot targets and customary closing conditions.
Redwood AI (OTCQB:RDWCF) began developing a Chemical Risk Assessment Module within its Reactosphere platform and appointed Dr. Noah Burns as Scientific Advisor.
The module aims to enhance chemical safety, risk assessment, and dual-use oversight while strengthening Reactosphere and Q-SAFE tools for hazardous chemical screening, classification, and R&D decision-making.
Redwood AI (OTCQB:RDWCF) signed a non-binding LOI with Dr. Placide Sesonga of the University of Global Health Equity in Rwanda to explore an AI-enabled pathogen tracking and outbreak intelligence initiative across Rwanda and the DRC.
The parties plan to design “One-health” surveillance infrastructure using genomics, geospatial analytics, and Redwood’s AI platform, targeting high-risk mobility corridors. The LOI supports protocol development and funding discussions, with any future binding agreements subject to separate definitive contracts. Redwood AI also reported the immediate resignation of director Graydon Bensler.
Redwood AI Corp (OTCQB: RDWCF) announced its inclusion in an AINewsWire editorial highlighting its next-generation intelligence platform at the intersection of AI, defense technology and post-quantum cybersecurity.
The company is described as having Silicon Valley roots, Canadian government and law-enforcement partnerships, and a proposed post-quantum cybersecurity acquisition.
Redwood AI (OTCQB:RDWCF) filed a provisional patent application with the USPTO for a Reactosphere optimization-module technology titled “Method of Chemical Experimental Optimization with Predictive-Accuracy-Based Sample-Size Planning.”
The invention targets more efficient chemical R&D by planning experiment sample sizes to support reliable, model‑guided optimization across multiple chemistry-driven industries.
Redwood AI (CSE:AIRX, OTCQB:RDWCF) signed a non-binding LOI to potentially acquire Vancouver-based Quantum.IQ, a post-quantum cybersecurity software company serving high-security sectors.
The contemplated all-share deal includes up to 7,000,000 shares at closing plus 7,000,000 milestone shares, all subject to multi-stage escrow and customary due diligence and regulatory approvals, with no assurance of completion.
Redwood AI (CSE:AIRX, OTCQB:RDWCF) announced a collaboration with Vancouver-based Resilience Biosciences to advance AI-assisted small-molecule drug development. Resilience will use Redwood's platform for computational chemistry, including derivative generation, IP-aware workflows, and retrosynthetic analysis, targeting more efficient discovery for non-opioid therapeutics in addiction, pain, and neuropsychiatric disorders.